Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

EuroPCR 2025 | DANAMI-3-DEFER: 10-Year Results of Deferred vs. Conventional Stenting in STEMI Patients

Primary percutaneous coronary intervention (PCI) with stent implantation is the recommended treatment for ST-segment elevation myocardial infarction (STEMI). However, immediate stent implantation can lead to distal embolization, microvascular damage, and impaired coronary flow, potentially resulting in adverse clinical outcomes. The aim of this study was to evaluate the 10-year clinical outcomes of deferred stent implantation versus conventional PCI in STEMI patients.

The primary endpoint (PEP) was a composite of all-cause mortality and heart failure (HF) hospitalization. The secondary endpoint (SEP) included the individual components of the PEP, cardiovascular mortality, recurrent myocardial infarction (MI), and target vessel revascularization.

Out of a total of 1215 patients, 603 were randomized to deferred stent implantation and 612 to conventional PCI. After 10 years of follow-up, deferred stent implantation did not entail a significant reduction in the PEP (hazard ratio [HR]: 0.82; 95% confidence interval [CI]: 0.67–1.02; p = 0.08). In the deferred group, 124 patients (24%) died compared to 150 patients (25%) in the conventional PCI group (HR: 0.95; 95% CI: 0.75–1.19). However, the HF hospitalization rate was significantly lower in the deferred group compared to the conventional group (odds ratio [OR]: 0.58; 95% CI: 0.39–0.88). The target vessel revascularization rate was similar between the two groups (OR: 1.20; 95% CI: 0.81–1.79).

Conclusion

The 10-year follow-up of the DANAMI-3-DEFER study showed that deferred stent implantation did not significantly reduce all-cause mortality or the composite primary endpoint, but it was associated with a lower rate of HF hospitalization compared to conventional PCI. 

Reference: Jacob Thomsen Lønborg et al. at EuroPCR 2025.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Andrés Rodríguez
Dr. Andrés Rodríguez
Member of the Editorial Board of solaci.org

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...